The Scleroderma Foundation is relaunching itself under a new name, the National Scleroderma Foundation, intending to reach and educate…
Yedida Y Bogachkov PhD
Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Yedida Y Bogachkov PhD
Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several…
Patients with scleroderma are more likely to develop restrictive lung disease (RLD) — a precursor to interstitial lung…
A higher rate of systemic sclerosis (SSc), very early diagnosis of systemic sclerosis (VEDOSS), and Raynaud’s phenomenon is…
Black patients with scleroderma are at higher risk of mortality and serious complications such as interstitial lung disease…
Cudetaxestat, a potential anti-scarring medication, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA)…
A celebrity lineup is slated for an upcoming fundraiser by the Scleroderma Research Foundation (SRF) to support disease research.